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Viruses that persist in infected hosts must evolve successful strategies to avoid recognition by the immune system. The
primary player in antiviral immune surveillance is the CD8/ cytotoxic T lymphocyte (CTL), and the battle drawn between
the CTLs and viruses is the focus of this review. In this struggle, viruses can follow multiple distinct pathways. For example,
DNA viruses often adopt the strategy of encoding proteins that interfere with the immune response along routes of antigen
presentation. Such interference prevents the viral peptide from binding to the major histocompatibility complex (MHC) class
I glycoprotein; therefore, no virus–MHC complex forms for recognition by antiviral CTLs. RNA viruses, having fewer genes,
generate swarms of quasispecies that can contain mutated viral proteins. When such mutants occur in viral peptides
presented to the MHC protein or the residue recognized by the CTL receptor, CTL recognition and activation fail. If, instead,
the mutation occurs in the viral peptide flanking sequence, the infected cell may not process the viral peptide from the
cytosol to the endoplasmic reticulum. Viruses can also directly or indirectly attack dendritic cells and CD4/ or CD8/ T
lymphocytes, other routes that interfere with immune functions. Dendritic cells are the primary professional antigen-present-
ing cells and are critical for the activation of CTL responses. CD4/ T lymphocytes provide help for long-term CD8/ CTL
activity and are necessary for its maintenance. Consequently, interference with either dendritic or CD4/ cell types constitutes
yet another way that viruses can disable the immune response and persistently infect their host. q 1997 Academic Press
The specific immune response generated by a host play of viral structural proteins on cell surfaces occurs
against infecting viruses can be segregated into two dis- late in the infectious cycle, and large amounts of antibody
tinct pathways: humoral (antibody) and cellular (T lym- (5 1 106 molecules) and complement are required to
phocytes). Both routes play important roles in protection lyse infected cells (Sissons et al., 1979). In the absence
from or prevention of viral infections, although clinical of complement, antibodies can bind to viral proteins on
and basic research results point to the T lymphocyte as the cell’s surface and alter viral transcription inside the
the major player in most viral infections. With the excep- cell (Fujinami and Oldstone, 1979; Levine and Griffin,
tion of several enteroviral infections, most viral infections 1992; Levine et al., 1991). In contrast, T cells need recog-
are controlled even by humans born with genetic defi- nize only a portion (peptide) of viral protein expressed
ciencies in antibody production and with little or no im- on the cell surface complex with the host major histo-
munoglobulin (Good, 1991; Whitton and Oldstone, 1996). compatibility (MHC) molecule (reviewed in Whitton and
Children with Bruton’s sex-linked a-gammaglobulinemia Oldstone, 1996). Viral proteins (peptides) recognized in-
not only recover in the absence of detectable antibody clude those made immediately after infection. Recent evi-
but resist subsequent exposure to most viruses, indicat- dence indicates that a single peptide complexed to the
ing that they also have and retain immune memory. How- appropriate MHC glycoprotein on a target cell can elicit
a CTL response (Sykulev et al., 1996). The fact that Tever, in those with impaired T cell responses, such as
individuals with DiGeorge’s syndrome (congenital cells offer defense against a virus during the intracellular
phase of its life cycle, coupled with these cells’ extraordi-athymic aplasia), acquired immunodeficiency syndrome
(AIDS), or leukemia, or those receiving immunosuppres- nary sensitivity and ability to recognize immediate-early
nonstructural components of the virus, which allows re-sive therapy, the frequency and severity of viral infections
are enhanced. In most instances, there is also some moval of the factories that make new viruses prior to
assembly, serves to make T cells a most formidable op-impairment of antibody responses, yet adoptive transfer
of hyperimmune immunoglobulin can moderate, but often ponent of viruses. In addition to lysing virally infected
cells, CTLs also inhibit viral gene expression by a noncy-is unable to clear, the viral infection. Antibodies, most
often through their hypervariable regions, recognize viral totoxic mechanism involving release of soluble factors
such as interferon-g and tumor necrosis factor (TNF)antigens as intact proteins that are circulating in the
blood and other fluids or that are attached to cell mem- (Guidotti et al., 1994).
Class I MHC-restricted CTLs play a pivotal role inbranes (Whitton and Oldstone, 1996). However, the dis-
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aborting and preventing both acute and persisting viral
infections. The presentation of viral peptide (antigens)
by MHC class I molecules utilizes primarily a cytosolic
pathway, and MHC class I molecules are found on nearly
all nucleated cells of the body except neurons (Joly et
al., 1991). The absence of MHC molecules in neurons is
one of the cardinal reasons why such cells, when in-
fected by viruses, are not lysed by CTL. The selective
advantage for the host is that these essential, nonre-
placeable cells are not destroyed, but viruses also enjoy
the advantage of dwelling in a cell where they avoid
immunologic surveillance. Hence, it is not surprising that
many DNA and RNA viruses reside in and persistently
infect neurons. The intracellular processing of viral pep-
tides so they can combine with MHC molecules occurs
in the endoplasmic reticulum (ER) and is a critical step in
FIG. 1. Antigen presentation by the MHC class I and class II path-the antigen-presenting pathway (Figs. 1 and 2). Neurons
ways (adapted from Whitton and Oldstone, 1996). For the class I path-escape antigen processing by failing to transcribe the
way, the thick line represents a viral protein newly synthesized in the
heavy chain of the MHC molecule (Joly et al., 1991) and cell’s cytoplasm. The protein is degraded to shorter peptides in the
not transcribing proteins that are important in trans- proteasome. A change in amino acid residues flanking the CTL epitope
(peptide) sequence can abort cleavage at this step. Peptides are trans-porting viral peptides to the ER (Joly and Oldstone, 1992).
located into the ER by the TAP transport mechanism. Shown schemati-In cells other than neurons, a basic and active strategy
cally are two peptides (l and s) that are both transported to the ER.used by viruses to avoid immune recognition, which
One of these (s) is selected on the basis of its binding affinity by the
would destroy the cell they wish to take over for produc- MHC molecule, followed by assembly of the MHC class I heavy chain
tion of their own progeny, is to neutralize or abort host peptide and MHC class I light chain (b2M). The MHC–peptide complex
passes into the Golgi and trans-Golgi to reach the cell’s surface, wheremolecules important in the antigen presentation path-
it is available to circulating CD8/ CTLs. For the class II pathway, theway. Alternatively, viruses can mutate their own amino
viral protein outside the cell is taken up by endocytosis and internalizedacids required for binding to MHC molecules in the ER
to reach an acid vesicle where degradation to peptide fragments takes
or to T cell receptors (TCR). Figure 1 depicts antigen place. Meanwhile, the class II molecule is synthesized within the ER
processing via both class I and class II pathways. and transported through the Golgi network where the class II molecule-
containing vesicle fuses with the endosome containing the fragmentedWithin the cell’s cytosol, newly synthesized viral pro-
protein. The class II molecule does not bind to peptides transportedteins are degraded into peptides by the ubiquitin-pro-
into the ER because another protein, the invariant chain (not shown),teasome system (Rechsteiner et al., 1993; Lowe et al.,
occupies the binding site. Later, in the endosome, the invariant chain
1995; Driscoll and Goldberg, 1990). Structurally, the is degraded or lost, allowing the MHC class II molecule to bind, again
proteasome particle consists of a 20S catalytic core of by selective affinity, to the peptide. Finally, the MHC–peptide complex
is transported to the cell’s surface where it is sought by CD4/ T cells.four donut-shaped heptameric stacks of homologous
subunits. Inside the core’s cavity are catalytic sites.
Additional subunits assemble with the 20S core to form
CTL epitopes have been found within signal se-a 26S complex that degrades intact proteins in an ATP-
quences (Hudrisier et al., 1997).dependent manner. The protein’s peptide fragments
Two fundamentally different tacks can be employedthen pass into the ER through the action of transport-
by viruses to interfere with antigen presentation. First,associated proteins (TAP) (Townsend and Trowsdale,
the DNA viruses associated with persistent infections1993). Figure 1 shows at least two viral peptides (a
are likely to encode gene products that interfere withblack circle and a white circle) that have been trans-
any of the multiple steps along the antigen-presentingported into the ER. One of these (the white circle) is
pathway (reviewed Fruh et al., 1997). DNA or RNA vi-selected on the basis of binding affinity to the a and
ruses that generate greater numbers of CD4/ thanb chains of the class I molecule’s heavy chain. The
CD8/ CTLs likely signal a defect in antigen presenta-conformation of the complex formed by this binding is
tion because the MHC class I pathway evolved to han-altered by its interaction with the MHC light chain (b2
dle cytosolic infections. The MHC class II pathway andmicroglobulin), allowing the completed complex to
CD4/ T cells are initiated through an extracellularpass into and through the Golgi to the cell surface.
route (Fig. 1). CD4/ CTLs were found several years agoPeptides degraded from whole proteins can also reach
in humans with herpes simplex virus (HSV) infectionthe MHC class I heavy chain, but in a TAP-independent
(Yasukawa and Zarling, 1984), although in most othermanner, when they originate from signal sequences
viral infections studied, including HSV infection of miceand are translated on ribosomes bound to the rough
ER (Henderson et al., 1992). Although not common, (Vasilakos and Michael, 1993; Niemialtowski et al.,
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1994), and in a recent study of HSV infection of humans
(Posavad et al., 1996), CD8/ CTLs are generated. The
reason for the generation of CD4/ anti-HSV CTLs was
unclear until others showed that HSV ICP-47 efficiently
blocked antigen presentation in human cells but did
so poorly in murine cells (York et al., 1994; Fruh et al.,
1995; Hill et al., 1995; Ahn et al., 1996a). The HSV
protein ICP-47 inhibits binding of its peptides to TAP,
a molecule necessary for translocating the peptide
from the cytosol to the ER. Currently, three proteins of
human cytomegalovirus (HCMV) that inhibit MHC class
I antigen presentation have been identified. One is the
US11 protein, which exports the MHC heavy chain from
the ER into the cytosol (Jones et al., 1995; Wiertz et al.,
1996); another is US3, which retains MHC molecules
in the ER, preventing them from traveling to the plasma
membrane (Ahn et al., 1996b). A third protein, US6,
inhibits peptide translocation by TAP (Ahn et al., 1997).
The m152 protein of murine cytomegalovirus (MCMV)
prevents MHC trafficking out of the ER (Tahle et al.,
1995), whereas MCMV p34 binds to MHC class I mole-
cules on the plasma membrane and prevents their in-
teraction with the TCR (Hill et al., 1996). Recently Slater FIG. 2. Schematic profile of the effect of a single amino acid mutation
and Campbell (1997) noted that the MCMV-induced (1, m) in the sequence (l) flanking the 9-amino-acid peptide (s) that
is processed to bind to the MHC class I molecule. The MHC-bounddefect in MHC class I synthesis and transport varied
peptide is presented at the cell’s surface for recognition by the T cellin a cell-specific manner, perhaps dependent upon the
receptor (TCR) of the CD8/ CTL. In row 1, the polypeptide is degradedstate of differentiation or transcriptional activity of the
appropriately in the proteasome and translocated by TAP molecules
infected cell. The adenovirus E3/19K glycoprotein was to the ER, where it binds tightly to the MHC molecule. The peptide–
the first viral component shown to inhibit MHC class I MHC complex then binds correctly to the TCR (motif A). In row 2, a
mutation in the flanking residue prevents recognition and processingantigen presentation (Burgert and Kvist, 1985; Anders-
by the proteasome. In rows 3 and 4, mutations in the CTL epitopeson et al., 1985). This viral complex resides in the ER,
peptide occur either at the residue facing the TCR (1) or at the anchorand the 6 amino acid residues terminating the 15-
residue (m) that binds to the MHC. In the first instance (motif B), al-
membered cytoplasmic tail of its gp19 component are though binding of the viral CTL epitope to the MHC and transport of
necessary and sufficient for retention in the ER (Nils- the complex to the cell’s surface are not impeded, binding to the TCR
does not occur. In the latter instance (motif C), the viral CTL epitopeson et al., 1989; Jackson et al., 1990). When these last
does not bind within the MHC heavy chain groove, b2microglobulin6 amino acids (DEKKMP) are transplanted onto the
does not lock into place, and the MHC–peptide complex does not formcytoplasmic tails of other membrane proteins that nor-
in the ER. This figure was modified from the Journal of Experimental
mally travel out of the ER, their ability to leave the ER Medicine, 1994, Vol. 180, pp. 779–782, by copyright permission of the
is eliminated. This inhibition of MHC class I antigen Rockefeller University Press.
presentation by the adenovirus E3 complex has been
confirmed both in vitro and in vivo (Efrat et al., 1995;
von Herrath et al., 1997). However, to date, none of the the immunodominant peptide would influence its pro-
cessing and block presentation to MHC molecules inHSV, HCMV, or MCMV proteins has been shown to
interfere with MHC class I antigen presentation in vivo, the ER (Eisenlohr et al., 1992). Accordingly, effective
processing of the Friend/Moloney/Rauscher (FMR)so their biological significance has not yet been estab-
lished. There is no reason why a specific gene prod- peptide RSPWFTTL encoded by MV-p15E led to the
defective processing of the FMR peptide in tumor cells,uct(s) of RNA viruses cannot also interfere with antigen
processing (Howcroft et al., 1993), and some do. while the KSPWFTTL peptide encoded by AKV-MCF
was processed correctly (Ossendorp et al., 1996). Sub-Second, RNA viruses have attracted attention be-
cause of their potentially high frequency of mutation sequent experiments showed that proteasome-medi-
ated digestion due to the R r K change led to degrada-in the viral peptides that interfere with processing from
the cytosol to the ER and because of their ability to bind tion of the peptide and its failure to present TAP for
translocation into the ER.to MHC class I molecules or to TCR (Fig. 2). Recently, a
single amino acid change in a viral peptide was shown Both in vitro evidence and in vivo evidence indicate
that viruses can escape recognition of virus-specific CTLto influence antigen processing. It had been antici-
pated that such a mutation in a viral sequence flanking by generating mutants in the viral peptide that binds to
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MHC molecules or is recognized by the TCR (Aebischer recent serial observations of CTL escape variants in
HIV infection (Borrow et al., 1997). That is, within 15et al., 1991; Lewicki et al., 1995a; Koup, 1994; Pircher et
al., 1990; Lewicki et al., 1995b; Moskophidis and Zinker- days after initiation of a primary HIV infection, a single
immunodominant epitope in gp160, amino acids 29 –nagel, 1995; Borrow et al., 1997; Goulder et al., 1997;
Harrer et al., 1996; Klenerman et al., 1994; Bertoletti et 39, engaged in a monospecific MHC class I restricted
CTL response that rapidly eliminated the infecting vi-al., 1994; Couillin et al., 1995). The MHC-bound peptide
sequence is linear, resulting from proteolytic fragmenta- ruses. At that time, no CTL responses to the other HIV
proteins occurred, so the kinetics for generation of ation of viral protein synthesized within the cell. Several
rules concerning the structure of these peptides and their CTL escape variant under CTL pressure in vivo could
be accurately measured. By 30 to 72 days after onsetbinding to MHC as well as the peptide–MHC complex
binding the TCR are now established. Studies of endoge- of the acute retroviral symptoms, and under CTL pres-
sure in which approximately 1 of every 20 CD8/ CTLnously processed viral peptides indicate that they vary
in length from 8 to 11 amino acids and display MHC lymphocytes in the blood was directed against that
single gp160 aa 29 – 39 epitope, this HIV peptide mu-allele-specific motifs. Mutational and crystallographic
studies of MHC molecules complexed with viral peptide tated, allowing the virus to escape CTL recognition.
The kinetics of CTL escape was comparable to thatshow that the molecule’s flexible conformations allow
these 8- to 11-amino-acid peptides to bind within the observed for patients receiving anti-retroviral drug
therapy and clearly indicated for the first time the bio-MHC groove once their anchoring residues are fixed
(Bjorkman et al., 1987; Garcia et al., 1996). Analysis of logical significance of generating such CTL responses
in vivo in HIV infection for the control of viral loadresidues flanking the anchoring residue(s) indicates the
critical importance of minor pockets of MHC-binding (Borrow et al., 1997). In the HIV-infected patient, a new
CTL epitope located near the COO0 end of gp160 andclefts in peptide selectivity, leading to the concept that
these structural factors are likely responsible for the pref- CTL responses to GAG, POL, and NEF now appeared
for the first time (Borrow et al., 1997). The newly gener-erential selection of specific peptides so often observed
in interactions with MHC molecules (Garcia et al., 1996; ated CTL responses continued to limit the viral load,
which dropped from 200,000 – 300,000 to approxi-Hudrisier et al., 1996; reviewed in Whitton and Oldstone,
1996). mately 1000 RNA molecules/ml. Similar results oc-
curred in experiments with LCMV (Lewicki et al.,Studies with lymphocytic choriomeningitis virus
(LCMV) have documented CTL escape variants with mu- 1995b) in that following mutation additional CTL epi-
topes were generated and the viral load was con-tations in all the known immunodominant epitopes se-
lected under CTL pressure (Lewicki et al., 1995a). By this trolled.
Goulder et al. (1997) also noted CTL escape variantsmeans, viral mutants are generated that escape recogni-
tion by CTL because of a single amino acid mutation in two HIV-infected patients studied during the late
stages of disease. These and other mutations in the CTLin any one of the known three immunodominant CTL
epitopes. These mutations did not occur at the anchor epitope may also inhibit CTL activation by an ‘‘antagonist
activity.’’ Described in both HIV and hepatitis B virus in-residue but at residues that interact with receptors for
the CTL. However, as long as one of these three immuno- fections (Klenerman et al., 1994; Bertoletti et al., 1994),
such mutated sequences can bind and interact with thedominant epitopes does not mutate, viruses are cleared
efficiently and effectively with the usual kinetics just as TCR (in contrast to the B motif shown in Fig. 2) but are
unable to deliver a full stimulatory signal so that anergythough all three were present (Lewicki et al., 1995b).
Importantly, when all three immunodominant epitopes occurs. The molecular basis of this failed response is
not clear.mutate in the same virion, the host can still mount nonim-
munodominant lower affinity CTLs against the virus and If CTL escape variants are unlikely to lead to viral
persistence, except when a uniquely restricted MHCstill control infection. However, in this case, more time
is required to purge virus infection (Lewicki et al., 1995b; allele(s) is present (de Campos-Lima et al., 1993) or
when only a monotypic CTL response is made (PircherMoskophidis and Zinkernagel, 1995). Thus, under CTL
pressure, escape variants can arise, but the host has et al., 1990; Borrow et al., 1997), what accounts for the
failure of CTL to control the infection? Since expres-other options including a hierarchical control of CTL epi-
topes that function even when immunodominant epi- sion of a single CTL epitope is apparently sufficient
for control of viral infection (Lewicki et al., 1995b), thetopes mutate. The inference drawn is that, unless a par-
ticular CTL response is restricted to one epitope (Pircher existence of a virus that evades immune surveillance
because a few or several of its CTL epitopes haveet al., 1990), even mutations in CTL epitopes (viral pep-
tide) identifiable by biochemical and in vitro assays are mutated is unlikely. Although one to three immuno-
dominant CTL epitopes have been found for a singleprobably not of major importance in persistent viral infec-
tions. viral protein, the numbers of viral proteins encoded in
the genome, the presence of two major MHC HLA-This hypothesis receives further reinforcement from
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restricting haplotypes per individual, and the hierar- effectively escape the host’s immune surveillance. De-
fining the parameters and manipulating the playerschical control and subsequent release of nonimmuno-
dominant CTL epitopes when the immunodominant involved promise to be important strategies in the
treatment of persistent viral infections.epitopes have mutated all indicate that it would likely
be rare for a virus to totally escape CTL recognition
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